
Erectile Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Erectile Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.
Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 1, 9, 8, 1, 17, 4 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 2 molecules, respectively.
Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.
Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 1, 9, 8, 1, 17, 4 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 2 molecules, respectively.
Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
- The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Companies Mentioned
AnyGen Co Ltd
Aprogen Inc
Aquestive Therapeutics Inc
Arovella Therapeutics Ltd
Astellas Pharma Inc
Autotelic Bio Inc
Benuvia Therapeutics Inc
Biozeus Pharmaceutical SA
Can-Fite BioPharma Ltd
Chengdu Dikang Pharmaceuticals Co Ltd
Cure Pharmaceutical Holding Corp
Dicot AB
Evincis Bio Inc
Exopharm Ltd
Fabre-Kramer Pharmaceuticals Inc
Farmalider SA
Guangzhou Four-Leaf Clover HealthTech Co Ltd
Hemostemix Inc
Humanetics Corp
ILGEN Inc
Initiator Pharma AS
IntelGenx Corp
Jiangsu Hengrui Medicine Co Ltd
Klaria Pharma Holding AB
Lexaria Bioscience Corp
MannKind Corp
Mezzion Pharma Co Ltd
MicroCures Inc
Mitsubishi Tanabe Pharma Corp
MyX Therapeutics Inc
NAL Pharmaceuticals Ltd
Organicell Regenerative Medicine Inc
Orgenesis Inc
PeLeMed Co Ltd
Pharmicell Co Ltd
Reven Holdings Inc
S1 Biopharma Inc
Seelos Therapeutics, Inc.
Shandong Lukang Pharmaceutical Co Ltd
siRNAgen Therapeutics Corp
Targazyme Inc
Tavanta Therapeutics Inc
Techfields Pharma Co Ltd
Tritech Biopharmaceuticals Co Ltd
Venturis Therapeutics Inc
XuanZhu Biological Technology Co Ltd
Yangtze River Pharmaceutical Group
Companies Mentioned
AnyGen Co Ltd
Aprogen Inc
Aquestive Therapeutics Inc
Arovella Therapeutics Ltd
Astellas Pharma Inc
Autotelic Bio Inc
Benuvia Therapeutics Inc
Biozeus Pharmaceutical SA
Can-Fite BioPharma Ltd
Chengdu Dikang Pharmaceuticals Co Ltd
Cure Pharmaceutical Holding Corp
Dicot AB
Evincis Bio Inc
Exopharm Ltd
Fabre-Kramer Pharmaceuticals Inc
Farmalider SA
Guangzhou Four-Leaf Clover HealthTech Co Ltd
Hemostemix Inc
Humanetics Corp
ILGEN Inc
Initiator Pharma AS
IntelGenx Corp
Jiangsu Hengrui Medicine Co Ltd
Klaria Pharma Holding AB
Lexaria Bioscience Corp
MannKind Corp
Mezzion Pharma Co Ltd
MicroCures Inc
Mitsubishi Tanabe Pharma Corp
MyX Therapeutics Inc
NAL Pharmaceuticals Ltd
Organicell Regenerative Medicine Inc
Orgenesis Inc
PeLeMed Co Ltd
Pharmicell Co Ltd
Reven Holdings Inc
S1 Biopharma Inc
Seelos Therapeutics, Inc.
Shandong Lukang Pharmaceutical Co Ltd
siRNAgen Therapeutics Corp
Targazyme Inc
Tavanta Therapeutics Inc
Techfields Pharma Co Ltd
Tritech Biopharmaceuticals Co Ltd
Venturis Therapeutics Inc
XuanZhu Biological Technology Co Ltd
Yangtze River Pharmaceutical Group
Table of Contents
106 Pages
- Introduction
- Global Markets Direct Report Coverage
- Erectile Dysfunction - Overview
- Erectile Dysfunction - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Erectile Dysfunction - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Erectile Dysfunction - Companies Involved in Therapeutics Development
- AnyGen Co Ltd
- Aprogen Inc
- Aquestive Therapeutics Inc
- Arovella Therapeutics Ltd
- Astellas Pharma Inc
- Autotelic Bio Inc
- Benuvia Therapeutics Inc
- Biozeus Pharmaceutical SA
- Can-Fite BioPharma Ltd
- Chengdu Dikang Pharmaceuticals Co Ltd
- Cure Pharmaceutical Holding Corp
- Dicot AB
- Evincis Bio Inc
- Exopharm Ltd
- Fabre-Kramer Pharmaceuticals Inc
- Farmalider SA
- Guangzhou Four-Leaf Clover HealthTech Co Ltd
- Hemostemix Inc
- Humanetics Corp
- ILGEN Inc
- Initiator Pharma AS
- IntelGenx Corp
- Jiangsu Hengrui Medicine Co Ltd
- Klaria Pharma Holding AB
- Lexaria Bioscience Corp
- MannKind Corp
- Mezzion Pharma Co Ltd
- MicroCures Inc
- Mitsubishi Tanabe Pharma Corp
- MyX Therapeutics Inc
- NAL Pharmaceuticals Ltd
- Organicell Regenerative Medicine Inc
- Orgenesis Inc
- PeLeMed Co Ltd
- Pharmicell Co Ltd
- Reven Holdings Inc
- S1 Biopharma Inc
- Seelos Therapeutics, Inc.
- Shandong Lukang Pharmaceutical Co Ltd
- siRNAgen Therapeutics Corp
- Targazyme Inc
- Tavanta Therapeutics Inc
- Techfields Pharma Co Ltd
- Tritech Biopharmaceuticals Co Ltd
- Venturis Therapeutics Inc
- XuanZhu Biological Technology Co Ltd
- Yangtze River Pharmaceutical Group
- Erectile Dysfunction - Drug Profiles
- ACP-01 - Drug Profile
- Product Description
- Mechanism Of Action
- AGM-175 - Drug Profile
- Product Description
- Mechanism Of Action
- alprostadil - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AN-788 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Antisense RNAi Oligonucleotides for Atopy, Erectile Dysfunction, Heart Failure and Psoriasis - Drug Profile
- Product Description
- Mechanism Of Action
- AP-185 - Drug Profile
- Product Description
- Mechanism Of Action
- apomorphine - Drug Profile
- Product Description
- Mechanism Of Action
- avanafil - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Biologics for Erectile Dysfunction - Drug Profile
- Product Description
- Mechanism Of Action
- BZ-371 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Cellgram-ED - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Cevaris - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CF-602 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CMS-203 - Drug Profile
- Product Description
- Mechanism Of Action
- CVBT-141 - Drug Profile
- Product Description
- Mechanism Of Action
- DDCI-01 - Drug Profile
- Product Description
- Mechanism Of Action
- Drug for Erectile Dysfunction - Drug Profile
- Product Description
- Mechanism Of Action
- EVI-200 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- fadanafil - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- FKK-01PD - Drug Profile
- Product Description
- Mechanism Of Action
- genistein - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ILG-F - Drug Profile
- Product Description
- Mechanism Of Action
- IPED-2015 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- libiguins - Drug Profile
- Product Description
- Mechanism Of Action
- mirabegron ER - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PLM-201 - Drug Profile
- Product Description
- Mechanism Of Action
- Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction - Drug Profile
- Product Description
- Mechanism Of Action
- RPCV-1005A - Drug Profile
- Product Description
- Mechanism Of Action
- S1P-205 - Drug Profile
- Product Description
- Mechanism Of Action
- siFi-2 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- sildenafil - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- sildenafil - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- sildenafil citrate - Drug Profile
- Product Description
- Mechanism Of Action
- sildenafil citrate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- sildenafil ODF - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
- Product Description
- Mechanism Of Action
- Stem Cell Therapy for Erectile Dysfunction - Drug Profile
- Product Description
- Mechanism Of Action
- Stem Cell Therapy for Premature Ovarian Failure and Erectile Dysfunction - Drug Profile
- Product Description
- Mechanism Of Action
- SUD-003 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SVF-CLI/ED - Drug Profile
- Product Description
- Mechanism Of Action
- tadalafil - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tadalafil - Drug Profile
- Product Description
- Mechanism Of Action
- tadalafil - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tadalafil - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tadalafil - Drug Profile
- Product Description
- Mechanism Of Action
- tadalafil IR - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TF-0092 - Drug Profile
- Product Description
- Mechanism Of Action
- TPN-171 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TPN-729 - Drug Profile
- Product Description
- Mechanism Of Action
- udenafil - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- vardenafil - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- vardenafil hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Yonkenafil - Drug Profile
- Product Description
- Mechanism Of Action
- Erectile Dysfunction - Dormant Projects
- Erectile Dysfunction - Discontinued Products
- Erectile Dysfunction - Product Development Milestones
- Featured News & Press Releases
- Mar 03, 2022: CURE Pharmaceutical and Milagro Pharmaceuticals collaborate for registration and approval to sell sildenafil oral thin film in Mexico
- Feb 21, 2022: Dicot has identified several new patent opportunities
- Dec 21, 2021: European Association of Urology has selected Dicot's study result to be presented
- Dec 06, 2021: Dicot's study results will be presented at a leading scientific congress
- Dec 02, 2021: Dicot's potency drug candidate demonstrates efficiency and long duration even at a low dose
- Nov 16, 2021: CURE Pharmaceutical receives patent approval for Its CUREfilm Blue Technology
- Oct 20, 2021: Due to positive study results Dicot publishes a supplement prospectus
- Sep 24, 2021: Initiator Pharma includes the first patient in Phase 2b study with IPED2015 in erectile dysfunction patients
- Sep 14, 2021: Lukang Pharmaceutical CMS203 tablets obtained the Notice of Drug Clinical Trial Approval" "
- Aug 24, 2021: Dicot: Proven long-term effect for Dicot’s drug candidate
- Jun 28, 2021: Initiator Pharma receives CTA approval for Phase 2b study with IPED2015 in Erectile Dysfunction patients
- Jun 02, 2021: Initiator Pharma - Phase 2a study with IP2018 update
- Apr 21, 2021: CURE Pharmaceutical announces successful results from initial clinical trials for erectile dysfunction product CUREfilm Blue
- Mar 24, 2021: Dicot begins its first studies on sick animals
- Mar 18, 2021: Can-Fite: Topical administration of CF602 fully recovers erectile dysfunction in diabetic model
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Erectile Dysfunction, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Companies, 2022 (Contd..2)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Erectile Dysfunction - Pipeline by AnyGen Co Ltd, 2022
- Erectile Dysfunction - Pipeline by Aprogen Inc, 2022
- Erectile Dysfunction - Pipeline by Aquestive Therapeutics Inc, 2022
- Erectile Dysfunction - Pipeline by Arovella Therapeutics Ltd, 2022
- Erectile Dysfunction - Pipeline by Astellas Pharma Inc, 2022
- Erectile Dysfunction - Pipeline by Autotelic Bio Inc, 2022
- Erectile Dysfunction - Pipeline by Benuvia Therapeutics Inc, 2022
- Erectile Dysfunction - Pipeline by Biozeus Pharmaceutical SA, 2022
- Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, 2022
- Erectile Dysfunction - Pipeline by Chengdu Dikang Pharmaceuticals Co Ltd, 2022
- Erectile Dysfunction - Pipeline by Cure Pharmaceutical Holding Corp, 2022
- Erectile Dysfunction - Pipeline by Dicot AB, 2022
- Erectile Dysfunction - Pipeline by Evincis Bio Inc, 2022
- Erectile Dysfunction - Pipeline by Exopharm Ltd, 2022
- Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, 2022
- Erectile Dysfunction - Pipeline by Farmalider SA, 2022
- Erectile Dysfunction - Pipeline by Guangzhou Four-Leaf Clover HealthTech Co Ltd, 2022
- Erectile Dysfunction - Pipeline by Hemostemix Inc, 2022
- Erectile Dysfunction - Pipeline by Humanetics Corp, 2022
- Erectile Dysfunction - Pipeline by ILGEN Inc, 2022
- Erectile Dysfunction - Pipeline by Initiator Pharma AS, 2022
- Erectile Dysfunction - Pipeline by IntelGenx Corp, 2022
- Erectile Dysfunction - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Erectile Dysfunction - Pipeline by Klaria Pharma Holding AB, 2022
- Erectile Dysfunction - Pipeline by Lexaria Bioscience Corp, 2022
- Erectile Dysfunction - Pipeline by MannKind Corp, 2022
- Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, 2022
- Erectile Dysfunction - Pipeline by MicroCures Inc, 2022
- Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
- Erectile Dysfunction - Pipeline by MyX Therapeutics Inc, 2022
- Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, 2022
- Erectile Dysfunction - Pipeline by Organicell Regenerative Medicine Inc, 2022
- Erectile Dysfunction - Pipeline by Orgenesis Inc, 2022
- Erectile Dysfunction - Pipeline by PeLeMed Co Ltd, 2022
- Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, 2022
- Erectile Dysfunction - Pipeline by Reven Holdings Inc, 2022
- Erectile Dysfunction - Pipeline by S1 Biopharma Inc, 2022
- Erectile Dysfunction - Pipeline by Seelos Therapeutics, Inc., 2022
- Erectile Dysfunction - Pipeline by Shandong Lukang Pharmaceutical Co Ltd, 2022
- Erectile Dysfunction - Pipeline by siRNAgen Therapeutics Corp, 2022
- Erectile Dysfunction - Pipeline by Targazyme Inc, 2022
- Erectile Dysfunction - Pipeline by Tavanta Therapeutics Inc, 2022
- Erectile Dysfunction - Pipeline by Techfields Pharma Co Ltd, 2022
- Erectile Dysfunction - Pipeline by Tritech Biopharmaceuticals Co Ltd, 2022
- Erectile Dysfunction - Pipeline by Venturis Therapeutics Inc, 2022
- Erectile Dysfunction - Pipeline by XuanZhu Biological Technology Co Ltd, 2022
- Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, 2022
- Erectile Dysfunction - Dormant Projects, 2022
- Erectile Dysfunction - Dormant Projects, 2022 (Contd..1)
- Erectile Dysfunction - Dormant Projects, 2022 (Contd..2)
- Erectile Dysfunction - Discontinued Products, 2022
- List of Figures
- Number of Products under Development for Erectile Dysfunction, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.